Community network driven COVID-19 testing of vulnerable populations in the Central US
Project Number3UG1DA050066-03S1
Contact PI/Project LeaderPOLLACK, HAROLD ALEXANDER Other PIs
Awardee OrganizationUNIVERSITY OF CHICAGO
Description
Abstract Text
This C3 project, Community network-driven COVID-19 testing of vulnerable populations in the Central
US, will implement and evaluate a COVID-19 testing approach that combines an evidence-based Social
Network Testing Strategy (SNS) with community developed COVID-19 public health messages (SNS+). C3 will
engage two disenfranchised populations across rural and urban sites in states across the Central US (TX, LA,
AR, IN, IL). C3 leverages NIDA's Justice Community Opioid Innovation Network (JCOIN), the PIs' extensive
community located COVID-19 testing programs, and a network of established community partnerships. The
collaborative community-academic partnerships, research and engagement infrastructure, and team's
leadership across JCOIN will ensure that C3 can rapidly recruit, enroll and test most disenfranchised
community members, (n=2400) and through this process, accelerate any forthcoming COVID-19 public health
prevention interventions. C3 focuses on two communities most impacted by COVID-19: 1) Criminal justice
involved (CJI) - non-incarcerated people with previous history of arrest/jail/prison, probation/parole and drug-
court attendance; and 2) Low-income Latinx - community members at 250% or below Federal Poverty Level.
Both of these diverse populations, and the overlap between them, have some of the highest rates of COVID-19
infection and death in the United States. Messaging that affirms individual agency and corrects misinformation,
combined with accessible and acceptable testing, is required to accelerate COVID-19 prevention for these
populations. We use contextually adapted and theory-driven messages – misinformation correction and self-
affirmation – to increase awareness, self-efficacy and community engagement in our adapted testing strategy –
the Social Network testing Strategy (SNS). SNS is an evidence-based testing intervention that has been widely
used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of
their social contacts into testing services. SNS combined with theory-driven, contextually appropriate COVID-
19 messaging (SNS+) will address challenges to current COVID-19 testing strategies which are limited by
misinformation, stigma, distrust, and limited affirmation of ability to prevent COVID-19. C3 in partnership with
community will: Develop COVID-19 messages that emphasize self-affirmation and misinformation correction
for implementation in SNS; Test the efficacy (number of network members COVID-19 tested) of a combined
SNS-messaging (SNS+) intervention versus standard SNS using adaptive randomization; and Evaluate C3
implementation strategies and key implementation outcomes (ie cost) using the RE-AIM framework. The
disenfranchised populations to be engaged in C3 reflect those most impacted by COVID-19 and least able to
adopt COVID-19 prevention practices. C3 is “shovel-ready” for implementation in the short timeframe of the
RADx-UP mechanism, with significant institutional commitments and community support, to ensure the
procedures and interventions are tailored, feasible, acceptable and effective for at-risk communities.
Public Health Relevance Statement
This C3 project, Community network-driven COVID-19 testing of vulnerable populations in the Central US, will
implement and evaluate a COVID-19 testing approach that combines an evidence-based Social Network
Testing Strategy with community developed COVID-19 public health messages. C3 will engage two
communities most impacted by COVID-19 in testing: 1) Criminal justice involved (CJI) - non-incarcerated
people with previous history of arrest/jail/prison, probation/parole and drug-court attendance; and 2) Low-
income Latinx - community members at 250% below Federal Poverty Level. The disenfranchised populations
to be engaged in C3 reflect those most impacted by COVID-19 and least able to adopt COVID-19 prevention
practices.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAdoptedAgeAwarenessCOVID-19COVID-19 impactCOVID-19 mortalityCOVID-19 preventionCOVID-19 susceptibilityCOVID-19 testingCommunitiesCommunity NetworksContact TracingCriminal JusticeDataDisease OutbreaksDrug CourtsEmploymentEnrollmentEnsureEthnic OriginFamilyFederally Qualified Health CenterFibrinogenFriendsGenderGenerationsHealthcareHouseholdHuman immunodeficiency virus testIndividualInfrastructureInterventionJailJusticeLatinxLeadLeadershipLinguisticsLow incomeMisinformationNational Institute of Drug AbuseOpioidPersonsPopulationPopulation HeterogeneityPrevention programPrisonsProceduresProcessPublic HealthRADx Underserved PopulationsRaceRandomizedReach Effectiveness Adoption Implementation and MaintenanceRecording of previous eventsResearchResourcesRiskRuralSARS-CoV-2 infectionSelf DeterminationSelf EfficacySiteSocial EnvironmentSocial NetworkSocial WorkTestingTrustUnited StatesVulnerable PopulationsWagescommunity centercommunity engagementcommunity partnershipcontextual factorscostdensitydisenfranchised populationdistrustefficacy testingevidence baseexperiencefederal poverty levelimplementation outcomesimplementation strategyinnovationmarginalized populationmemberparolepreferencepreventive interventionprobationprogramsrecruitruralitysecondary analysissocial contactsocial stigmasubstance usertesting servicestesting uptaketheoriestransmission process
No Sub Projects information available for 3UG1DA050066-03S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3UG1DA050066-03S1
Patents
No Patents information available for 3UG1DA050066-03S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3UG1DA050066-03S1
Clinical Studies
No Clinical Studies information available for 3UG1DA050066-03S1
News and More
Related News Releases
No news release information available for 3UG1DA050066-03S1
History
No Historical information available for 3UG1DA050066-03S1
Similar Projects
No Similar Projects information available for 3UG1DA050066-03S1